Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 HEXOZomedicaOrganiGramKnight TherapeuticsHLS Therapeutics
SymbolTSE:HEXONYSEAMERICAN:ZOMTSE:OGITSE:GUDTSE:HLS
Price Information
Current PriceC$7.14$0.98C$3.10C$5.30C$18.78
52 Week RangeBuyBuyHoldBuyBuy
MarketRank™
Overall Score0.70.91.41.71.4
Analysis Score1.31.53.93.53.7
Community Score2.13.01.83.03.1
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.01.31.90.0
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyBuy
Consensus Price TargetC$1.76$0.30C$4.10C$7.42C$30.50
% Upside from Price Target-75.35% downside-69.23% downside32.21% upside39.94% upside62.41% upside
Trade Information
Market CapC$873.84 million$550.01 millionC$966.15 millionC$682.45 millionC$597.62 million
BetaN/AN/AN/AN/AN/A
Average Volume2,414,775163,779,0784,734,682359,21538,452
Sales & Book Value
Annual RevenueC$111.62 millionN/AC$80.97 millionC$199.52 millionC$56.11 million
Price / Sales7.83N/A11.423.4210.65
CashflowC$0.93 per shareN/AC$0.47 per shareC$3.09 per shareC$0.63 per share
Price / Cash7.66N/A6.621.7129.63
Book ValueC$4.42 per shareN/AC$1.37 per shareC$6.82 per shareC$5.32 per share
Price / Book1.61N/A2.260.783.53
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($2.02)N/AC($0.92)C$0.32C($0.61)
Trailing P/E RatioN/A0.00N/A16.61N/A
Forward P/E Ratio
P/E GrowthN/AN/A0.23N/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AC$0.15
Dividend YieldN/AN/AN/AN/A0.79%
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio16.03%N/A37.74%6.34%66.02%
Current Ratio4.30%N/A2.66%4.84%1.29%
Quick Ratio2.37%N/A1.88%4.23%0.93%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees3741951667964
Shares Outstanding122.39 million564.05 million298.23 million128.76 million31.82 million
Next Earnings Date6/9/2021 (Estimated)5/10/2021 (Estimated)7/20/2021 (Estimated)6/25/2021 (Estimated)5/6/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
HLS Therapeutics (TSE:HLS) PT Raised to C$28.00 at Raymond JamesHLS Therapeutics (TSE:HLS) PT Raised to C$28.00 at Raymond James
americanbankingnews.com - March 30 at 3:30 PM
FY2021 EPS Estimates for HLS Therapeutics Inc. (TSE:HLS) Decreased by AnalystFY2021 EPS Estimates for HLS Therapeutics Inc. (TSE:HLS) Decreased by Analyst
americanbankingnews.com - March 28 at 1:48 AM
FY2021 EPS Estimates for HLS Therapeutics Inc. (TSE:HLS) Reduced by Raymond JamesFY2021 EPS Estimates for HLS Therapeutics Inc. (TSE:HLS) Reduced by Raymond James
americanbankingnews.com - March 26 at 7:38 AM
Equities Analysts Offer Predictions for HLS Therapeutics Inc.s FY2022 Earnings (TSE:HLS)Equities Analysts Offer Predictions for HLS Therapeutics Inc.'s FY2022 Earnings (TSE:HLS)
americanbankingnews.com - March 25 at 8:32 AM
HLS Therapeutics (TSE:HLS) Given New C$28.00 Price Target at Raymond JamesHLS Therapeutics (TSE:HLS) Given New C$28.00 Price Target at Raymond James
americanbankingnews.com - March 24 at 2:54 PM
Heres What Analysts Are Forecasting For HLS Therapeutics Inc. (TSE:HLS) After Its Annual ResultsHere's What Analysts Are Forecasting For HLS Therapeutics Inc. (TSE:HLS) After Its Annual Results
finance.yahoo.com - March 20 at 2:09 PM
HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial ResultsHLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results
finance.yahoo.com - March 18 at 7:07 AM
HLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference CallHLS Therapeutics to Host Q4 and Fiscal 2020 Financial Results Conference Call
markets.businessinsider.com - March 4 at 6:56 AM
HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on February 18, 2021
finance.yahoo.com - February 16 at 5:03 PM
Saladax Biomedical Announces Health Canada Approval of Five MyCare™ Psychiatry Laboratory Diagnostic AssaySaladax Biomedical Announces Health Canada Approval of Five MyCare™ Psychiatry Laboratory Diagnostic Assay
benzinga.com - February 16 at 12:03 PM
HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®HLS Therapeutics Provides Update on Private and Public Payer Reimbursement for Vascepa®
finance.yahoo.com - February 16 at 7:03 AM
VASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular EventsVASCEPA® (Icosapent Ethyl) Receives Further Inclusions in Guidelines from International Medical Societies for its Role in Reducing the Risk of Cardiovascular Events
finance.yahoo.com - January 28 at 8:46 AM
HLS Therapeutics Announces Update on Health Canada Filings for MyCare and TrinomiaHLS Therapeutics Announces Update on Health Canada Filings for MyCare and Trinomia
finance.yahoo.com - December 16 at 9:39 AM
HLS Therapeutics Establishes Automatic Share Purchase PlanHLS Therapeutics Establishes Automatic Share Purchase Plan
finance.yahoo.com - November 19 at 8:29 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting ProceduresVASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures
finance.yahoo.com - November 16 at 7:58 AM
Do Institutions Own HLS Therapeutics Inc. (TSE:HLS) Shares?Do Institutions Own HLS Therapeutics Inc. (TSE:HLS) Shares?
finance.yahoo.com - November 8 at 12:45 PM
HLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer BidHLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer Bid
finance.yahoo.com - November 5 at 8:13 AM
SVB opens new office in CanadaSVB opens new office in Canada
pehub.com - October 29 at 6:37 PM
On-Demand Pharmaceuticals Printing at BattlefieldOn-Demand Pharmaceuticals Printing at Battlefield
i-hls.com - October 21 at 1:08 PM
HLS Therapeutics gets a target raise from Clarus SecuritiesHLS Therapeutics gets a target raise from Clarus Securities
cantechletter.com - October 2 at 12:41 PM
HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent LitigationHLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation
finance.yahoo.com - September 3 at 2:11 PM
When Will HLS Therapeutics Inc. (TSE:HLS) Breakeven?When Will HLS Therapeutics Inc. (TSE:HLS) Breakeven?
finance.yahoo.com - August 10 at 1:28 PM
HLS Therapeutics misses on revenueHLS Therapeutics misses on revenue
seekingalpha.com - August 6 at 9:33 AM
HLS Therapeutics Announces Q2 2020 Financial ResultsHLS Therapeutics Announces Q2 2020 Financial Results
finance.yahoo.com - August 6 at 9:33 AM
HLS Therapeutics to Host Q2 2020 Financial Results Conference CallHLS Therapeutics to Host Q2 2020 Financial Results Conference Call
finance.yahoo.com - July 30 at 9:25 AM
DateCompanyBrokerageAction
3/19/2021HEXOMKM PartnersBoost Price Target
12/16/2020HEXOStifel NicolausUpgrade
12/15/2020HEXOATB CapitalUpgrade
12/15/2020HEXOCanaccord GenuityBoost Price Target
11/2/2020HEXOCormarkLower Price Target
11/2/2020HEXOStandpoint ResearchLower Price Target
6/17/2020HEXOJefferies Financial GroupBoost Price Target
6/12/2020HEXOCIBCBoost Price Target
6/12/2020HEXOEight CapitalLower Price Target
4/15/2020HEXOAlliance Global PartnersLower Price Target
11/16/2020ZomedicaHC WainwrightLower Price Target
4/14/2021OrganiGramHaywood SecuritiesLower Price Target
4/13/2021OrganiGramRaymond JamesLower Price Target
9/16/2020OrganiGramCantor FitzgeraldBoost Price Target
3/26/2021Knight TherapeuticsBloom BurtonUpgrade
3/25/2021Knight TherapeuticsNational Bank FinancialReiterated Rating
11/16/2020Knight TherapeuticsRoyal Bank of CanadaLower Price Target
1/2/2020HLS TherapeuticsClarus SecuritiesReiterated Rating
(Data available from 4/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.